Who is QIVIGY®
for?
QIVIGY is for adult patients with primary immunodeficiency who expect quality outcomes backed by high treatment satisfaction, efficient infusion experiences, proven efficacy, and steady protection from infection.1-3
Expect more with QIVIGY
Paige
31 years of age
Living with CVID
Hypothetical patient.
Paige is the proud aunt of twin boys, Oliver and Nathan, and a data analyst for a small startup. She was diagnosed 5 years ago and has been dissatisfied with her current IVIG for some time. She experiences flu-like symptoms after each infusion and substantial drops in energy at the tail end of her dose interval, making it difficult to keep up with her nephews. Paige needs an IVIG she can tolerate that provides steady IgG levels month to month.
QIVIGY is Paige's choice because:
- IgG trough levels had minimal fluctuations across both the 3- and 4-week dosing schedules2
- QIVIGY was proven highly tolerable in clinical trials with zero AEs leading to discontinuation, zero significant, life-threatening TEAEs, and zero serious AEs2
Lucas
22 years of age
Living with X-linked agammaglobulinemia
Hypothetical patient.
Lucas recently graduated from college and is starting his first full-time job as an events coordinator for a theater nonprofit. He is currently on an SCIG but still experiences breakthrough infections that require hospitalization from time to time. Lucas would like to switch to an IVIG that will deliver reliable protection with minimal adverse reactions and keep him out of the hospital.
QIVIGY is Lucas' choice because:
- QIVIGY was proven effective in clinical trials with zero hospitalizations across 12 months of treatment1
- ~97% of QIVIGY monthly infusions (623/643) were completed without rate reduction, interruption, or discontinuation2
There are no comparative head-to-head trials with QIVIGY.
Kelvin
67 years of age
Living with hypogammaglobulinemia
Hypothetical patient.
Kelvin is a retired law secretary and maintains a busy calendar as a volunteer city council member. He has a few comorbidities and limited dexterity that impairs his ability to self administer SCIG. Due to these considerations, his healthcare provider recommended he switch to an IVIG. Additionally, Kelvin is often on antibiotics for recurring bacterial infections, putting him at high risk for antibiotic resistance. He needs an IVIG that protects him from infection and reduces his dependence on antibiotics.
QIVIGY is Kelvin's choice because:
- Patients treated with QIVIGY in the trial spent 3% of the year on antibiotics1*
- QIVIGY was proven effective in clinical trials with zero acute serious bacterial infections† (99% confidence limit: 0.10; n=47)1,2
Paige
31 years of age
Living with CVID
Paige is the proud aunt of twin boys, Oliver and Nathan, and a data analyst for a small startup. She was diagnosed 5 years ago and has been dissatisfied with her current IVIG for some time. She experiences flu-like symptoms after each infusion and substantial drops in energy at the tail end of her dose interval, making it difficult to keep up with her nephews. Paige needs an IVIG she can tolerate that provides steady IgG levels month to month.
QIVIGY is Paige's choice because:
- IgG trough levels had minimal fluctuations across both the 3- and 4-week dosing schedules2
- QIVIGY was proven highly tolerable in clinical trials with zero AEs leading to discontinuation, zero significant, life-threatening TEAEs, and zero serious AEs2
Lucas
22 years of age
Living with X-linked agammaglobulinemia
Lucas recently graduated from college and is starting his first full-time job as an events coordinator for a theater nonprofit. He is currently on an SCIG but still experiences breakthrough infections that require hospitalization from time to time. Lucas would like to switch to an IVIG that will deliver reliable protection with minimal adverse reactions and keep him out of the hospital.
QIVIGY is Lucas' choice because:
- QIVIGY was proven effective in clinical trials with zero hospitalizations across 12 months of treatment1
- ~97% of QIVIGY monthly infusions (623/643) were completed without rate reduction, interruption, or discontinuation2
There are no comparative head-to-head trials with QIVIGY.
Kelvin
67 years of age
Living with hypogammaglobulinemia
Kelvin is a retired law secretary and maintains a busy calendar as a volunteer city council member. He has a few comorbidities and limited dexterity that impairs his ability to self administer SCIG. Due to these considerations, his healthcare provider recommended he switch to an IVIG. Additionally, Kelvin is often on antibiotics for recurring bacterial infections, putting him at high risk for antibiotic resistance. He needs an IVIG that protects him from infection and reduces his dependence on antibiotics.
QIVIGY is Kelvin's choice because:
- Patients treated with QIVIGY in the trial spent 3% of the year on antibiotics1*
- QIVIGY was proven effective in clinical trials with zero acute serious bacterial infections† (99% confidence limit: 0.10; n=47)1,2
*The median (min, max) duration of antibiotic treatment of any kind of infection was 10 days (1, 334). A total of 36 (76.6%) patients used at least 1 course of concomitant antibiotic therapy for treatment of infections. Eleven patients (23.4%) did not require antibiotic treatment.2
†Acute serious bacterial infections include bacterial pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, visceral abscesses, or bacterial meningitis.1
AE, adverse event; AR, adverse reaction; CVID, common variable immune deficiency; IgG, immune globulin G; IVIG, intravenous immune globulin; SCIG, subcutaneous immune globulin; TEAE, treatment-related adverse event.